BCL2 and ovarian carcinoma: DX in contrast is an anti-cancer drug that induces UPR/ER stress [48] and apoptosis by intercalating into a number of key DNA and RNA polymerases and altering the Bcl-2/Bax central checkpoint apoptosis pathways which are prevalent in ovarian cancer cells [49].